Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia

NCT00686010 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Type II Hyperlipidaemia

Interventions

DRUG: Placebo
DRUG: JTT-705 300mg
DRUG: JTT-705 600mg
DRUG: JTT-705 900mg

Sponsor

Japan Tobacco Inc.